Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.730
-0.010 (-0.57%)
At close: Feb 13, 2026, 4:00 PM EST
1.749
+0.019 (1.12%)
After-hours: Feb 13, 2026, 7:24 PM EST
Palisade Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
257.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 250.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 15.39K | -244.61K | -94.08% |
| Dec 31, 2018 | 260.00K | - | - |
| Dec 31, 2017 | 260.00K | 243.75K | 1,500.39% |
| Dec 31, 2016 | 16.25K | 5.83K | 55.96% |
| Dec 31, 2015 | 10.42K | -8.42K | -44.69% |
| Dec 31, 2014 | 18.83K | -91.17K | -82.88% |
| Dec 31, 2013 | 110.00K | -297.71K | -73.02% |
| Dec 31, 2012 | 407.71K | 17.08K | 4.37% |
| Dec 31, 2011 | 390.63K | -342.81K | -46.74% |
| Dec 31, 2010 | 733.44K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | 306.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 277.73M |
| Sutro Biopharma | 105.65M |
| Cellectis | 82.55M |
| Fennec Pharmaceuticals | 38.79M |
| Shattuck Labs | 1.00M |
| Neurogene | 925.00K |
| Avalo Therapeutics | 192.00K |
PALI News
- 5 days ago - Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - GlobeNewsWire
- 9 days ago - Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 16 days ago - Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board - GlobeNewsWire
- 4 weeks ago - Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - GlobeNewsWire
- 5 weeks ago - Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 - GlobeNewsWire
- 6 weeks ago - Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 - GlobeNewsWire
- 7 weeks ago - Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
- 2 months ago - Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development - GlobeNewsWire